Dosing is underway in the second stage of a Phase 1/2a clinical trial evaluating BioLineRx’s (NASDAQ:BLRX) AGI-134 in patients with solid tumors. Preliminary data should be available by year-end 2020.
The company says AGI-134, a synthetic alpha-Gal immunotherapy designed to be injected directly into a tumor, harnesses the body’s anti-Gal antibodies to induce a systemic, specific anti-tumor response to the patient’s own tumor neoantigens.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.